Merck agrees to allow Sinopharm to sell molnupiravir COVID drug in China
NEW YORK, Sept 28 (Reuters) – Drugmaker Merck & Co (MRK.N) said on Wednesday that it agreed to allow China’s Sinopharm (1099.HK) to distribute and import its COVID-19 antiviral molnupiravir in China if the drug is approved for use there.
The drugmaker said in a statement that it reached a cooperation framework agreement with Sinopharm that grants the Chinese company distribution and exclusive import rights of the medicine in the China mainland market.
Merck also said it will allow China National Biotec Group, an affiliate of Sinopharm, to make the drug in China and has agreed to transfer technology to help with that production.
Molnupiravir is sold under the brand name Lagevrio in the U.S. Merck developed the pill – and shares the profits equally – with partner Ridgeback Biotherapeutics.
The antiviral pill was once touted as a potential game changer for treating COVID-19, but Paxlovid, a rival drug made by Pfizer Inc , had significantly better results in its clinical trial and has been much more widely used in the United States.
Our Standards: The Thomson Reuters Trust Principles.